Remdesivir and Acute Renal Failure: A Potential Safety Signal From Disproportionality Analysis of the WHO Safety Database

Remdesivir is approved for emergency use by the US Food and Drug Administration (FDA) and authorized conditionally by the European Medicines Agency (EMA) for patients with coronavirus disease 2019 (COVID‐19). Its benefit‐risk ratio is still being explored because data in the field are rather scant....

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Clinical pharmacology and therapeutics 2021-04, Vol.109 (4), p.1021-1024
Hauptverfasser:	Gérard, Alexandre O., Laurain, Audrey, Fresse, Audrey, Parassol, Nadège, Muzzone, Marine, Rocher, Fanny, Esnault, Vincent L.M., Drici, Milou‐Daniel
Format:	Artikel
Sprache:	eng
Schlagworte:	Acute Kidney Injury - chemically induced Adenosine Monophosphate - adverse effects Adenosine Monophosphate - analogs & derivatives Adenosine Monophosphate - therapeutic use Alanine - adverse effects Alanine - analogs & derivatives Alanine - therapeutic use Antiviral Agents - adverse effects Antiviral Agents - therapeutic use COVID-19 - drug therapy Humans Odds Ratio Pharmacovigilance SARS-CoV-2 World Health Organization
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!